Last reviewed · How we verify
DOTAREM
DOTAREM is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the relaxation time of water protons in tissues.
DOTAREM is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the relaxation time of water protons in tissues. Used for MRI contrast enhancement for brain, spine, and body imaging, Contrast-enhanced MRI for detection and characterization of lesions in various tissues.
At a glance
| Generic name | DOTAREM |
|---|---|
| Also known as | gadoterate meglumine, Gadoterate meglumine, gadoteric acid, gadoterate meglumine, gadoteric acid, Dotarem 0.1 mmol/kg |
| Sponsor | Guerbet |
| Drug class | Gadolinium-based contrast agent |
| Target | Water proton relaxation (T1 and T2 relaxation times) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
DOTAREM contains gadolinium chelated with diethylenetriaminepentaacetic acid (DTPA), which distributes into extracellular fluid and increases signal intensity in MRI by altering the magnetic properties of nearby water molecules. This allows for improved visualization and characterization of tissues and lesions during MRI examinations.
Approved indications
- MRI contrast enhancement for brain, spine, and body imaging
- Contrast-enhanced MRI for detection and characterization of lesions in various tissues
Common side effects
- Headache
- Nausea
- Dizziness
- Injection site reactions
- Gadolinium retention (rare)
Key clinical trials
- Dotarem vs Gadobutrol Contrast for Breast MRI (PHASE4)
- Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.
- Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas (PHASE3)
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
- Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease (PHASE3)
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) (PHASE3)
- Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas
- Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DOTAREM CI brief — competitive landscape report
- DOTAREM updates RSS · CI watch RSS
- Guerbet portfolio CI